S91 A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis

Cough is a common, troublesome symptom in idiopathic pulmonary fibrosis (IPF), but the underlying mechanisms are poorly understood and effective therapies are lacking. VRP700 is thought to inhibit ion-channels found on sensory afferents innervating the airways. We aimed to investigate the efficacy of VRP700 in reducing cough frequency in patients with IPF. A single centre double-blind randomised, placebo controlled crossover study in patients …